Literature DB >> 10386858

Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta.

W J Jabs1, C Hennig, R Zawatzky, H Kirchner.   

Abstract

The presence of constitutively produced interferon (IFN)-alpha in the blood of healthy individuals has been the subject of contradictory discussions for years. Immunologic as well as biologic test procedures have demonstrated striking differences regarding serum IFN-alpha under physiologic conditions. We investigated the presence of immunoreactive IFN-alpha in serum samples of 923 healthy blood donors by means of a widely used commercially available ELISA. Of these, 254 (27.5%) exhibited detectable serum IFN-alpha levels. The sera of 85.1% of these people also contained IFN-beta. Both IFN were also demonstrated in EDTA-anticoagulated plasma. However, none of these samples exhibited any antiviral effect on human A549 lung carcinoma cells challenged with encephalomyocarditis virus. Samples with high IFN-alpha ELISA activity did not abolish the antiviral action of added natural IFN-alpha, thus excluding IFN-alpha inhibitory factors. The experiments suggest that the detected compounds probably did not represent IFN-alpha but were the result of a cross-reaction with unknown serum components. A variety of disorders has been associated with elevated serum IFN-alpha levels that in most cases were detected by ELISA. In view of our data, these findings need to be carefully reevaluated. For the purpose of monitoring IFN-alpha levels in therapy of atopic, autoimmune, or malignant disorders, an appropriate detection system for IFN-alpha is advisable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386858     DOI: 10.1089/107999099313901

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  18 in total

1.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

2.  Interferon-alpha: a therapeutic target in systemic lupus erythematosus.

Authors:  Mary K Crow
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

3.  Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.

Authors:  Xuan Feng; Diana Han; Bharat K Kilaru; Beverly S Franek; Timothy B Niewold; Anthony T Reder
Journal:  Arch Neurol       Date:  2012-10

4.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Authors:  Xuan Feng; Nicholas P Reder; Mounica Yanamandala; Addie Hill; Beverly S Franek; Timothy B Niewold; Anthony T Reder; Adil Javed
Journal:  J Neurol Sci       Date:  2011-10-27       Impact factor: 3.181

5.  IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.

Authors:  Timothy B Niewold; Jennifer A Kelly; Silvia N Kariuki; Beverly S Franek; Akaash A Kumar; Kenneth M Kaufman; Kenaz Thomas; Daniel Walker; Stan Kamp; Jacqueline M Frost; Andrew K Wong; Joan T Merrill; Marta E Alarcón-Riquelme; Mohammed Tikly; Rosalind Ramsey-Goldman; John D Reveille; Michelle A Petri; Jeffrey C Edberg; Robert P Kimberly; Graciela S Alarcón; Diane L Kamen; Gary S Gilkeson; Timothy J Vyse; Judith A James; Patrick M Gaffney; Kathy L Moser; Mary K Crow; John B Harley
Journal:  Ann Rheum Dis       Date:  2011-11-16       Impact factor: 19.103

6.  Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

Authors:  Timothy B Niewold; Jennifer A Kelly; Marie H Flesch; Luis R Espinoza; John B Harley; Mary K Crow
Journal:  Arthritis Rheum       Date:  2008-08

Review 7.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

8.  Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab.

Authors:  Christophe Richez; Thierry Schaeverbeke; Chantal Dumoulin; Joël Dehais; Jean-François Moreau; Patrick Blanco
Journal:  Arthritis Res Ther       Date:  2009-06-29       Impact factor: 5.156

9.  Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

Authors:  Timothy B Niewold; Silvia N Kariuki; Gabrielle A Morgan; Sheela Shrestha; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2009-06

10.  High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

Authors:  T B Niewold; J Hua; T J A Lehman; J B Harley; M K Crow
Journal:  Genes Immun       Date:  2007-06-21       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.